---
title: "Adrabetadex (Lembaz) in Infantile-onset Niemann-Pick disease type C: Pharmacodynamics"
description: "Formulary evidence on Adrabetadex (Lembaz, VTS-270) in Infantile-onset Niemann-Pick disease type C: Pharmacodynamics. Topics: Cerebrospinal fluid biomarkers after 52 weeks of treatment, Target engagement in mouse and cat models: company nonclinical studies, and Intracisternal administration in cats with Niemann-Pick disease type C1. 3 evidence topics quoted from 3 sources."
canonical: "https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/product-information-and-disease-description/pharmacodynamics"
published: "2026-11-19T12:08:36-05:00"
modified: "2026-11-19T12:08:36-05:00"
---

# Adrabetadex (Lembaz) in Infantile-onset Niemann-Pick disease type C: Pharmacodynamics

<a id="heading-2.1.2.6.2"></a>

## 2.1.2.6.2 Pharmacodynamics

<a id="topic-2.1.2.6.2-1"></a>

### Cerebrospinal fluid biomarkers after 52 weeks of treatment

> “Following 52 weeks of treatment with LEMBAZ in patients with NPC, increased concentration of 24(S)-hydroxycholesterol and decreased concentrations of calbindin D and FABP3 in CSF were observed compared to baseline.”
> “The clinical significance of these biomarker changes has not been established.”
> “Plasma 24(S)-hydroxycholesterol and CSF calbindin D and FABP3 changed in an exposure-dependent manner across the LEMBAZ dosage range of 200 to 900 mg administered intrathecally every 2 weeks.”
> “The exposure-response relationship and the time course of the safety and effectiveness of LEMBAZ has not been fully characterized.”

Source: [Lembaz prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/220996s000lbl.pdf)

<a id="topic-2.1.2.6.2-2"></a>

### Target engagement in mouse and cat models: company nonclinical studies

> “Target engagement is directly linked to CNS exposure: adrabetadex dose-dependently reduces intracellular cholesterol across brain regions and increases 24(S)-OHC, consistent with enhanced efflux of accumulated cholesterol from the CNS.”
> “Adrabetadex treatment significantly increased brain 24(S)-OHC (p=0.0008), 72 hours after the second 0.8 mg ICV dose.”
> “24(S)-OHC production is proportional to both trafficking capability and the size of the accumulated cholesterol pool, indicating the need for repeated and frequent administrations to counteract the rate of ongoing cholesterol accumulation in I-NPC.”

Source: [Burchard et al. (2026a)](https://medical.berentx.com/wp-content/uploads/2026/05/APMRF2026-P18.1-MOA.pdf)

<a id="topic-2.1.2.6.2-3"></a>

### Intracisternal administration in cats with Niemann-Pick disease type C1

> “In contrast, direct administration of HPβCD into the cisterna magna of presymptomatic cats with NPC disease prevented the onset of cerebellar dysfunction for greater than a year and resulted in a reduction in Purkinje cell loss and near normal concentrations of cholesterol and sphingolipids.”
> “Moreover, administration of intracisternal HPβCD to NPC cats with ongoing cerebellar dysfunction slowed disease progression, increased survival time, and decreased the accumulation of brain gangliosides.”

Source: [Vite et al. (2015)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4415615/)

## Related pages
- [Adrabetadex (Lembaz): Infantile-onset Niemann-Pick disease type C](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c) · [Markdown](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c.md)
- [Adrabetadex (Lembaz) in Infantile-onset Niemann-Pick disease type C: Terms and abbreviations](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/terms-and-abbreviations.md)
- [Adrabetadex (Lembaz): Infantile-onset Niemann-Pick disease type C](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/executive-summary) · [Markdown](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/executive-summary.md)
- [Adrabetadex (Lembaz) in Infantile-onset Niemann-Pick disease type C: Product information and disease description](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/product-information-and-disease-description.md)
- [Adrabetadex (Lembaz) in Infantile-onset Niemann-Pick disease type C: Clinical evidence](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/clinical-evidence.md)
- [Adrabetadex (Lembaz) in Infantile-onset Niemann-Pick disease type C: Economic information and modeling report](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/economics) · [Markdown](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/economics.md)
- [Adrabetadex (Lembaz) in Infantile-onset Niemann-Pick disease type C: References](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/references) · [Markdown](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/references.md)
